HemaSure/Cobe
This article was originally published in The Gray Sheet
Executive Summary
Cobe Labs invests $9 mil. in blood filtration technology firm HemaSure in exchange for 4.5 mil. shares of HemaSure common stock, giving Cobe 30.2% of the company. Cobe also gains an option to purchase an additional $3 mil. in stock between Aug. 3, 1999 and May 3, 2000, and representation on HemaSure's board of directors and its representative committees. Proceeds will go toward U.S. commercialization of HemaSure's r/LS red blood cell filtration system, for which 510(k) clearance is expected by July. Cobe will distribute the device in the U.S. In conjunction with the financing, the two firms have signed an amended exclusive distribution agreement making Cobe the worldwide distributor of HemaSure products, excluding sales to the American Red Cross
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.